Skip to main content
SpringerLink
Log in

Amlodipine, isradipine and lacidipine: longer-acting dihydropyridine calcium antagonists

  • New Drugs and Therapeutic
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Guidelines Sub-Committee. 1993 guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertension 1993; 11(9): 905–18

    Article  Google Scholar 

  2. Haria M, Wagstaff AJ. Amlodipine: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50(3): 560–86

    Article  PubMed  CAS  Google Scholar 

  3. Brogden RN, Sorkin EM. Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension. Drugs 1995; 49(4): 618–49

    Article  PubMed  CAS  Google Scholar 

  4. Brogden RN, McTavish D. Nifedipine gastrointestinal therapeutic system (GITS): a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Drugs 1995; 50(3): 495–512

    Article  PubMed  CAS  Google Scholar 

  5. Lee CR, Bryson HM. Lacidipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension. Drugs 1994; 48(2): 274–96

    Article  PubMed  CAS  Google Scholar 

  6. Kelly JG, O’Malley K. Clinical pharmacokinetics of calcium antagonists. Clin Pharmacokinet 1992; 22(6): 416–33

    Article  PubMed  CAS  Google Scholar 

  7. Fitton A, Benfield P. Isradipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1990; 40(1): 31–74

    Article  PubMed  CAS  Google Scholar 

  8. British National Formulary No. 29. London: The Pharmaceutical Press, 1995; 90–2

  9. Donnelly R, Elliott HL, Meredith PA. Concentration-effect analysis of antihypertensive drug response: focus on calcium antagonists. Clin Pharmacokinet 1994; 26(6): 472–85

    Article  PubMed  CAS  Google Scholar 

  10. Meredith PA, Elliott HL. FDA guidelines on trough:peak ratios in the evaluation of antihypertensive agents. J Cardiovasc Pharmacol 1994; 23 Suppl. 5: S26–30

    Article  PubMed  CAS  Google Scholar 

  11. Holmes DG. Isradipine: a slow-release formulation given once-daily controls blood pressure for 24H. Am J Hypertens 1993 Mar; 6 Suppl.: 74S–6S

    PubMed  CAS  Google Scholar 

  12. Hermans L, Deblander A, De Keyser P, et al. At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomised, parallel-group study. Br J Clin Pharmacol 1994; 38: 335–40

    Article  PubMed  CAS  Google Scholar 

  13. Cross BW, Kirby MG, Miller S, et al. A multicentre study of the safety and efficacy of amlodipine in mild to moderate hypertension. Br J Clin Pract 1993 Sep-Oct; 47: 237–40

    PubMed  CAS  Google Scholar 

  14. Kloner RA, Sowers JR, DiBona GF, et al. Women have a higher response rate than men to the antihypertensive calcium channel blocker amlodipine [abstract no. 901–114], J Am Coll Cardiol 1995 Feb Spec. Iss.: 32A-3A

  15. Lüscher TF, Waeber B. Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial. J Cardiovasc Pharmacol 1993 Feb; 21: 305–9

    Article  PubMed  Google Scholar 

  16. Feiks A, Grunberger W, Meisner W. Influence of isradipine on the maternal and fetal cardiovascular system in hypertensive disorders in pregnancy. Am J Hypertens 1991 Feb; 4 Suppl.: 200–2

    Google Scholar 

  17. Wide-Swensson DH, Ingermarsson I, Lunell N-O, et al. Calcium channel blockade (isradipine) in the treatment of hypertension in pregnancy. A randomised placebo-controlled study. Am J Obstet Gynecol. In press

  18. Van den Dorpel MA, Zietse R, Ijzermans M, et al. Effect of isradipine on cyclosporin A-related hypertension. Blood Press 1994; 3 Suppl. 1: 50–3

    Google Scholar 

  19. McClellan K. Unexpected results from MIDAS in atherosclerosis. In-pharma 1994 Apr 9; (932): 4

  20. Schwarz T. Shedding more light on MIDAS. Inpharma 1994 Jul 16; (946): 3–4

  21. Higgins G. MIDAS revisited: perhaps atherosclerosis was not to blame? Inpharma 1995 Jan 28; (971): 3–4

  22. Chahine RA, Feldman RL, Giles TD. Randomized placebo-controlled trial of amlodipine in vasospastic angina. J Am Coll Cardiol 1993; May; 21: 1365–70

    Article  PubMed  CAS  Google Scholar 

  23. Packer M, Nicod P, Khandheria BR, et al. Randomized, multicenter, double-blind, placebo-controlled evaluation of amlodipine in patients with mild-to-moderate heart failure [abstract]. J Am Coll Cardiol 1991 Feb; 17 Suppl. A: 274

    Article  Google Scholar 

  24. Higgins G. New therapeutic proposals for chronic heart failure studies. Inpharma 1995 Apr 1; (980): 3–5

  25. Kubota K, Pearce GL, Inman WHW. Vasodilation-related adverse effects in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring. Eur J Clin Pharmacol 1995; 48: 1–7

    Article  PubMed  CAS  Google Scholar 

  26. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993 Jan 25; 153: 154–83

    Article  Google Scholar 

  27. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995 Aug 23–30; 274: 620–5

    Article  PubMed  CAS  Google Scholar 

  28. Henahan S. Industry & academia respond to calcium antagonist controversy. Inpharma 1995 Apr 1; (980): 13–14

  29. UWASH calcium-channel blocker study supports JNC V approach to hypertension; CCB companies contest finding of increased risk v. beta blockers, diuretics. FDC Reports — Pink Sheet 1995 Mar 20; 57(2): 16–17

    Google Scholar 

  30. NHLBI panel stands by JNC V in response to Circulation CCB article; AIM report supports use of beta blockers for prevention of sudden cardiac death. FDC Reports — Pink Sheet 1995 Sep 4; 57(36): 3–4

    Google Scholar 

  31. Pfizer Norvasc use in hypertensive patients shows 3.9 myocardial infarctions per 1000 patient years, firm claims: CCB makers dispute Washington study results. FDC Reports — Pink Sheet 1995 Aug 28; 57: 14

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Amlodipine, isradipine and lacidipine: longer-acting dihydropyridine calcium antagonists. Drugs Ther. Perspect 6, 1–5 (1995). https://doi.org/10.2165/00042310-199506090-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199506090-00001

Search

Navigation